Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)

Business Wire November 9, 2021

Zymeworks to Present at Upcoming Investor Conferences

Business Wire November 8, 2021

Zymeworks Reports 2021 Third Quarter Financial Results

Business Wire November 3, 2021

Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers

Business Wire October 26, 2021

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors

Business Wire October 5, 2021

Zanidatamab Phase 2 Clinical Trial Demonstrates Promising Response Rate and Durability in First-Line HER2-Positive Gastroesophageal Adenocarcinoma (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

Business Wire September 16, 2021

Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress

Business Wire September 12, 2021

Zymeworks Reports 2021 Second Quarter Financial Results

Business Wire August 4, 2021

Zymeworks Announces Milestone Payment as Janssen Achieves First Patient Dosed for its Bispecific Antibody Utilizing Zymeworks' Azymetric(TM) and EFECT(TM) Therapeutic Platforms

Business Wire August 3, 2021

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

Business Wire July 28, 2021

Zymeworks to Present at Ladenburg Thalmann Healthcare Conference

Business Wire July 8, 2021

Zymeworks to Present at Jefferies Virtual Healthcare Conference

Business Wire May 26, 2021

Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting

Business Wire May 6, 2021

Zymeworks Reports 2021 First Quarter Financial Results

Business Wire May 5, 2021

Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors

GlobeNewswire April 20, 2021

Zymeworks Announces Succession Plan for Chief Medical Officer

Business Wire April 19, 2021

Zymeworks to Present at Bloom Burton Healthcare Conference

Business Wire April 13, 2021

Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT(TM), and Zanidatamab Mechanisms of Action at AACR Annual Meeting

Business Wire April 10, 2021

Zymeworks Announces Five Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

Business Wire March 10, 2021

Zymeworks Reports 2020 Year-End Financial Results

Business Wire February 24, 2021